- Home
- AQST vs CRVS Comparison
AQST vs CRVS Comparison
Compare AQST & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- CRVS
- Stock Information
- Founded
- AQST 2004
- CRVS 2014
- Country
- AQST United States
- CRVS United States
- Employees
- AQST N/A
- CRVS N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- AQST Health Care
- CRVS Health Care
- Exchange
- AQST Nasdaq
- CRVS Nasdaq
- Market Cap
- AQST 272.9M
- CRVS 305.4M
- IPO Year
- AQST 2018
- CRVS 2016
- Fundamental
- Price
- AQST $4.06
- CRVS $4.35
- Analyst Decision
- AQST Strong Buy
- CRVS Strong Buy
- Analyst Count
- AQST 7
- CRVS 4
- Target Price
- AQST $11.29
- CRVS $15.00
- AVG Volume (30 Days)
- AQST 1.3M
- CRVS 1.1M
- Earning Date
- AQST 08-05-2025
- CRVS 08-05-2025
- Dividend Yield
- AQST N/A
- CRVS N/A
- EPS Growth
- AQST N/A
- CRVS N/A
- EPS
- AQST N/A
- CRVS N/A
- Revenue
- AQST $54,228,000.00
- CRVS N/A
- Revenue This Year
- AQST N/A
- CRVS N/A
- Revenue Next Year
- AQST $45.71
- CRVS N/A
- P/E Ratio
- AQST N/A
- CRVS N/A
- Revenue Growth
- AQST 5.29
- CRVS N/A
- 52 Week Low
- AQST $2.12
- CRVS $1.96
- 52 Week High
- AQST $5.80
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- AQST 72.86
- CRVS 58.33
- Support Level
- AQST $3.62
- CRVS $4.08
- Resistance Level
- AQST $3.80
- CRVS $4.31
- Average True Range (ATR)
- AQST 0.19
- CRVS 0.28
- MACD
- AQST 0.05
- CRVS 0.02
- Stochastic Oscillator
- AQST 95.43
- CRVS 96.10
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).